| |
|
|
 |
Edith A Perez, MD
Professor of Medicine, Mayo Medical School
Director, Cancer Clinical Study Unit
Director, Breast Cancer Program, Division of
Hematology and Oncology, Mayo Clinic
Jacksonville, Florida
|
|
| |
Click here to download the entire interview |
|
|
| Track 1 |
Predictors of response to adjuvant endocrine
therapy |
|
| Track 2 |
TAnDEM study: Anastrozole with or without
trastuzumab as first-line therapy of metastatic
disease |
|
| Track 3 |
NCCTG-N0337: Nonalopecic regimen of
capecitabine, vinorelbine and trastuzumab as
first- or second-line therapy |
|
| Track 4 |
Use of adjuvant trastuzumab monotherapy for
elderly patients |
|
| Track 5 |
Perspective on the second interim analysis of
BCIRG 006 |
|
| Track 6 |
Efficacy and safety results from the second
interim analysis of BCIRG 006 |
|
| Track 7 |
Incorporation of ACE inhibitors with
AC  taxane/trastuzumab to ameliorate
cardiotoxicity |
|
| Track 8 |
Role of TCH in treating HER2-positive, early
breast cancer |
|
| Track 9 |
Treatment for smaller, HER2-positive, node-negative
tumors |
|
| Track 10 |
Clinical trials combining bevacizumab with
chemotherapy/trastuzumab for HER2-positive
disease |
|
| Track 11 |
Background of BIG 2-06: Adjuvant Lapatinib
and/or Trastuzumab Treatment Optimization
study (ALTTO) |
|
| Track 12 |
Eligibility for ALTTO |
|
| Track 13 |
Treatment randomization on ALTTO |
|
| Track 14 |
Safety and efficacy data with trastuzumab and
lapatinib in combination |
|
| Track 15 |
Lapatinib cardiac safety data |
|
| Track 16 |
First-line therapy after progression on a trastuzumab-containing regimen |
|
| Track 17 |
Continuing clinical development of nanoparticle
albumin-bound (nab) paclitaxel |
|
| Track 18 |
Weekly or every three-week nab paclitaxel versus
docetaxel as first-line therapy |
|
|
|
paclitaxel with or without gemcitabine
for node-positive breast cancer
